Vivos (OTCQB: RDGL) received U.S. FDA approval for a Feasibility Investigational Device Exemption (IDE), allowing a first-in-human U.S. clinical feasibility study of RadioGel® Precision Radionuclide Therapy for non-resectable papillary thyroid carcinoma.
The Mayo Clinic study in Jacksonville will initially enroll five patients and assess safety and feasibility of yttrium-90-based RadioGel®. Vivos also continues commercial IsoPet® expansion and international PrecisionGel™ licensing efforts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.